Arcutis Biotherapeutics Inc (NASDAQ:ARQT) has a beta value of 1.18 and has seen 0.52 million shares traded in the recent trading session. The company, currently valued at $1.09B, closed the recent trade at $9.44 per share which meant it gained $0.14 on the day or 1.52% during that session. The ARQT stock price is -39.51% off its 52-week high price of $13.17 and 81.36% above the 52-week low of $1.76. The 3-month trading volume is 3.02 million shares.
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) trade information
Sporting 1.52% in the green today, the stock has traded in the green over the last five days, when the ARQT stock price touched $9.44 or saw a rise of 4.16%. Year-to-date, Arcutis Biotherapeutics Inc shares have moved 192.29%, while the 5-day performance has seen it change 6.32%. Over the past 30 days, the shares of Arcutis Biotherapeutics Inc (NASDAQ:ARQT) have changed 9.02%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcutis Biotherapeutics Inc (ARQT) estimates and forecasts
Figures show that Arcutis Biotherapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 186.09% over the past 6 months, with this year growth rate of 57.67%, compared to 15.50% for the industry.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -48.07% over the past 5 years. Earnings growth for 2024 is a modest 55.07% while over the next 5 years, the company’s earnings are expected to increase by 9.80%.
ARQT Dividends
Arcutis Biotherapeutics Inc is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
